Prostate-Specific Antigen Velocity Risk Count Assessment: A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability - 09/08/11
, Anna Kettermann a, Luigi Ferrucci b, Patricia Landis a, E. Jeffrey Metter b
Reprint requests: H. Ballentine Carter, M.D., Department of Urology, Marburg 145, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287.Résumé |
Objectives |
To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer.
Methods |
The PSAV was determined in 717 men (606 without prostate cancer; 32 with high-risk prostate cancer defined as death from cancer, PSA level of 20 ng/mL or more, or a Gleason score of 8 or more; and 79 with prostate cancer who were alive or dead of another cause). Multiple PSAVs determined from three repeated measures from each subject during 10 to 20 years were used to determine the risk count by summing the number of times a subject exceeded a PSAV threshold. Cox proportional hazards regression analysis was used to evaluate the associations between the risk count and the probability of high-risk disease. The statistical tests were two-sided.
Results |
The probability of high-risk disease increased directly with the risk count. After adjusting for age, PSA level, PSAV, and date of diagnosis, the PSAV risk count was significantly associated with the development of high-risk prostate cancer (relative risk 1.41, 95% confidence interval 1.25 to 1.59 for a PSAV cutpoint 0.2 ng/mL/yr; relative risk 1.49, 95% confidence interval 1.29 to 1.71 for a PSAV cutpoint of 0.4 ng/mL/yr; P <0.001).
Conclusions |
The PSAV risk count could be a useful method of interpreting a PSA history to help identify those men who will benefit from a diagnosis of prostate cancer at PSA levels associated with curable disease.
Le texte complet de cet article est disponible en PDF.Plan
| This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging, Baltimore, Maryland. |
Vol 70 - N° 4
P. 685-690 - octobre 2007 Retour au numéro
Article précédent
- Does Experimental Pain Assessment Before Biopsy Predict for Pain During Transrectal Ultrasound-Guided Prostate Biopsy?
- Sedat Soyupek, Murat Bozlu, Abdullah Armağan, Alper Özorak, Hakki Perk
- High Yield of Saturation Prostate Biopsy for Patients with Previous Negative Biopsies and Small Prostates
- Kamran P. Sajadi, Timothy Kim, Martha K. Terris, James A. Brown, Ronald W. Lewis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?